<DOC>
	<DOCNO>NCT01765426</DOCNO>
	<brief_summary>The purpose study compare safety , tolerability immunogenicity Takeda 's Tetravalent Dengue Vaccine Candidate ( TDV ) [ previously DENVax ] administer intradermally varied dose schedule via different method administration ( conventional needle/syringe versus needle-free PharmaJet® injector ) .</brief_summary>
	<brief_title>Phase 1b Study Investigating Safety &amp; Immunogenicity TDV Given Intradermally Needle Needle-Free PharmaJet Injector</brief_title>
	<detailed_description>This exploratory trial ass safety , tolerability immunogenicity vaccination tetravalent dengue vaccine ( TDV ) healthy adult deliver intradermally use conventional needle/syringe needle-free PharmaJet® injector . Two ( 2 ) intradermal injection either vaccine placebo administer qualified participant ( one arm ) Day 0 study . A subsequent injection also give Day 90 either vaccine placebo ( one arm ) . Participants evaluate safety dengue neutralize antibody four serotypes . All participant also evaluate injection site reaction blood drawn viremia , neutralize antibody , cell mediate immunity innate immunity . Participants required participate approximately 10 month recruitment collection data primary outcome ( Day 120 ) include collection additional sample measurement long term antibody titer ( Day 270 ) . This project fund whole part Federal fund National Institute Allergy Infectious Diseases , National Institutes Health , Department Health Human Services , Contract No . HHSN272201000034C .</detailed_description>
	<criteria>In good health determine medical history physical examination ( include blood pressure heart rate ) . Negative human immunodeficiency virus1 ( HIV1 ) antibody , Hepatitis C antibodies &amp; Hepatitis B surface antigen . Females negative urine pregnancy test screen immediately prior injection , willing use reliable mean contraception . Body Mass Index ( BMI ) ≤ 35 kg/m^2 . Any Grade 2 abnormality screen laboratory test . History Dengue Fever , Japanese Encephalitis , West Nile Yellow Fever disease . Seropositivity dengue West Nile virus . Extensive scar tattoo ( &gt; 50 % ) arm , shoulder , neck face head . History significant dermatologic disease last 6 month . Receipt plan receipt vaccine 4 week precede follow Day 0 90 vaccination . Any planned travel dengue endemic area include Caribbean , Mexico , Central America , South America Southeast Asia , study period month prior screen . Use systemic corticosteroid therapy within previous 6 month ( dose 0.5 mg/kg/day ) . Topical prednisone permit currently use use within last month prior first vaccination . Use prescribed medication 7 day first injection . Previous vaccination clinical study approve product Dengue Fever , Yellow Fever Japanese Encephalitis . Known suspect congenital acquire immunodeficiency receipt immunosuppressive therapy last 6 month . Planned donation blood period study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prophylactic vaccination</keyword>
</DOC>